Quality Control Responsibilities in Pharmaceutical GMP

In short: Pharmaceutical Quality Control (QC) covers more than laboratory testing: it helps ensure that sampling, specifications, testing, records and product-quality decisions follow approved requirements. Its responsibilities include maintaining suitable laboratory controls, reviewing results, supporting investigations and monitoring product quality over time.

What does Quality Control do?

QC connects sampling and laboratory results with decisions about the quality of materials and products. EU GMP describes QC as covering sampling, specifications, testing, documentation and release procedures, and treats its independence from Production as fundamental (EudraLex Volume 4, Part I, Chapter 6, Principle and §§6.1–6.3).

For products within the scope of US current good manufacturing practice, the quality control unit has authority to approve or reject specified materials and drug products, review production records for errors and investigations, and approve or reject procedures and specifications that affect product identity, strength, quality or purity (21 CFR 211.22). Responsibilities and procedures must be written and followed.

The exact authority and hand-offs depend on the applicable market requirements and the manufacturer’s approved quality system.

Main responsibilities of a pharmaceutical QC department

Maintain specifications, methods and laboratory controls

QC establishes or maintains the controlled specifications and written procedures needed for sampling and testing. Laboratory staff, premises and equipment should be suitable for the work. Test methods should be validated; when a laboratory adopts a method it did not validate, it should verify that the method is suitable for its use (EudraLex Volume 4, Part I, Chapter 6, §§6.5–6.7 and 6.15).

QC also oversees appropriate calibration or qualification and maintenance records for instruments. Reagents, solutions, reference standards, glassware and culture media need controls proportionate to their use. For example, applicable procedures should address preparation, status, storage and expiry information; culture media performance should be checked before use (Chapter 6, §§6.7 and 6.19–6.24).

Plan and document sampling

Sampling should follow approved written procedures. These procedures describe the sampling method and equipment, quantity, containers, identification, storage conditions, precautions and cleaning or storage of sampling equipment. Samples should represent the batch, and the sampling plan should be justified using a risk-management approach. Sample labels and handling should help prevent mix-ups and protect sample quality (Chapter 6, §§6.11–6.13).

Test materials and review results

QC performs or oversees testing against the approved specification and method. Test records should make the work traceable: identify the material or product and batch, the applicable method and specification, results and calculations, test dates, the people who performed and checked the work, the equipment used, and the resulting status decision (Chapter 6, §§6.15–6.18).

Calculations should be critically checked. Results for critical quality attributes should be reviewed for consistency and trends. Out-of-specification (OOS) or out-of-trend (OOT) results should be addressed and investigated under written procedures (Chapter 6, §§6.7 and 6.9).

Support product assessment and ongoing quality monitoring

QC contributes to finished-product assessment by considering relevant production conditions, in-process results, manufacturing and packaging records, specification compliance and the finished pack. The department also oversees reference or retention samples where applicable, product stability monitoring and participation in quality-related complaint investigations (Chapter 6, §§6.2–6.3).

Batch disposition and release roles must be assigned in the applicable regulations and written procedures. Do not assume the same sign-off arrangement applies in every country or quality system.

Retain QC records

QC documentation linked to a batch record must be retained under the applicable GMP record-retention rules. Keep batch-associated records for at least 1 year after the expiry date of the respective product batch. Under EU GMP Chapter 4 §4.11, batch documentation must be kept for one year after batch expiry or at least five years after Qualified Person certification, whichever is longer. For records covered by US cGMP, 21 CFR 211.180(a) also sets a minimum of one year after batch expiry. Apply any longer period required by applicable local law or the product’s marketing authorisation.

Related reading

• Quality Control Testing of Raw Materials, APIs, and Finished Products
• SOP for Analyst Qualification of a Quality Control Analyst
• Records Maintenance in a Quality Control Laboratory
• GMP Requirements for Certificates of Analysis

Frequently asked questions

Is Quality Control limited to laboratory testing?

No. QC also supports controlled sampling, documentation, investigation of atypical results, product assessment and ongoing monitoring of product quality.

Should QC be independent from Production?

EudraLex Volume 4, Part I, Chapter 6 identifies QC’s independence from Production as fundamental. The manufacturer’s organisation and written procedures should define responsibilities and escalation paths.

What information should a QC test record contain?

It should identify the tested material or product and batch, the relevant method and specification, results and calculations, dates, the people performing and checking the work, equipment used, and the resulting status decision, as applicable to the test.

How long should QC batch records be kept?

At least one year after the expiry date of the respective product batch. EU GMP Chapter 4 §4.11 requires the longer of that period or five years after Qualified Person certification for batch documentation. US cGMP records covered by 21 CFR 211.180(a) have the one-year-after-expiry minimum; other applicable requirements may require longer.

References

• European Commission, EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Part I, Chapter 6: Quality Control (revision dated 28 March 2014; effective 1 October 2014), especially Principle and §§6.1–6.3, 6.5–6.18, 6.19–6.24, 6.26–6.35. Official text.
• European Commission, EudraLex Volume 4, Chapter 4: Documentation (revision 1, January 2011), especially §§4.10–4.12. Official text.
• U.S. Food and Drug Administration, Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 211 (eCFR current through 14 October 2026), §§211.22 and 211.180(a). §211.22 · §211.180.